Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

Abstract

Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (alpha-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.

• Authors: Silvia Brunelli, Clara Sciorati, Giuseppe D'Antona, Anna Innocenzi, Diego Covarello, Beatriz G Galvez, Cristiana Perrotta, Angela Monopoli, Francesca Sanvito, Roberto Bottinelli, Ennio Ongini, Giulio Cossu, Emilio Clementi
• Journal: Proceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 104 Issue 1 Pg. 264-9 (Jan 02 2007) ISSN: 0027-8424 [Print] United States
• PMID: 17182743 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Nitric Oxide Donors
• Sarcoglycans
• nitroflurbiprofen
• Flurbiprofen
• Prednisolone
• Creatine Kinase

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Apoptosis (drug effects)
• Combined Modality Therapy
• Creatine Kinase (blood)
• Flurbiprofen (analogs & derivatives, pharmacology)
• Mice
• Muscle, Skeletal (drug effects, physiopathology)
• Muscular Dystrophy, Animal (pathology, therapy)
• Muscular Dystrophy, Duchenne (pathology, therapy)
• Nitric Oxide Donors (therapeutic use)
• Prednisolone (pharmacology)
• Regeneration (drug effects)
• Sarcoglycans (physiology)
• Stem Cell Transplantation